<DOC>
	<DOCNO>NCT01029847</DOCNO>
	<brief_summary>Investigation wholebody MRI circulate biomarkers inflammation , cartilage bone metabolism patient spondyloarthritis treat adalimumab . Furthermore compare ultrasound examination wholebody MRI etc .</brief_summary>
	<brief_title>Adalimumab Axial Spondyloarthritis ( ASIM ) - MRI Biomarkers Patients With Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Spondyloarthritis ( SpA ) accord new ASAS criterion axial SpA BASDAI &gt; 40 mm despite NSAIDs Clinical indication treatment TNFalpha inhibitor Age &gt; 18 year old &lt; 85 year old Sufficient contraception woman Capable give informed consent Capable comply examination program protocol Pregnancy wish , pregnancy breastfeeding DMARDs within 4 week prior inclusion Oral , intraarticular intramuscular glucocorticoid within 4 week prior inclusion The use study drug within 4 week prior inclusion le 5 halflives study drug inclusion 4 week The use suspect diseasemodifying immunosuppressive drug within 4 week prior inclusion DMARDs allow study , dose change 4 week prior inclusion week Contraindications TNFÎ± inhibitor treatment Contraindications MRI Known recent drug alcohol abuse Failure provide write consent Incapable comply examination program physical mental reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Patients axial spondyloarthritis</keyword>
</DOC>